# Retatrutide References: Cited Clinical and Scientific Literature

> Full citation list for retatrutide research summarized on this site — Phase 1, 2, and 3 trials, structural biology, and recent 2024-2025 findings, with DOIs and PubMed links.

Every claim on this site cites a source from this list. DOIs and PubMed links provided throughout.

## Published clinical trials and research

All citations used across this site are listed below in numbered order, with full author information, journal, year, DOI, and PubMed or ClinicalTrials.gov URL where available.

## References

[1] Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. https://pubmed.ncbi.nlm.nih.gov/37366315/
[2] Rosenstock J, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial. Lancet. 2023;402(10401):529-544. https://pubmed.ncbi.nlm.nih.gov/37385280/
[3] Li W, Zhou Q, Cong Z, et al. Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide. Cell Discovery. 2024;10:77. https://pmc.ncbi.nlm.nih.gov/articles/PMC11255275/
[4] Urva S, Coskun T, Loh MT, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022;400:1869-1881. https://pubmed.ncbi.nlm.nih.gov/36354040/
[5] Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine. 2024;30:2037-2048. https://pmc.ncbi.nlm.nih.gov/articles/PMC11271400/
[6] Katsi V, Koutsopoulos G, Fragoulis C, Dimitriadis K, Tsioufis K. Retatrutide — A Game Changer in Obesity Pharmacotherapy. Biomolecules. 2025;15:796. https://pmc.ncbi.nlm.nih.gov/articles/PMC12190491/
[7] Eli Lilly and Company. A Study of Retatrutide (LY3437943) Once Weekly in Participants With Obesity and Type 2 Diabetes (TRIUMPH-2). ClinicalTrials.gov. 2023. https://clinicaltrials.gov/study/NCT05931367
[8] Eli Lilly and Company. The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Function. ClinicalTrials.gov. 2024. https://clinicaltrials.gov/study/NCT06383390
[9] Eli Lilly and Company. A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176). ClinicalTrials.gov. 2024. https://clinicaltrials.gov/study/NCT06662383
[10] Eli Lilly and Company. A Study of LY3437943 in Healthy Participants. ClinicalTrials.gov. 2019. https://clinicaltrials.gov/study/NCT04143802
[11] Bhat S, et al. Efficacy and safety of incretin co-agonists: Transformative advances in cardiometabolic healthcare. World Journal of Cardiology. 2025;17(8):107991. https://doi.org/10.4330/wjc.v17.i8.107991
[12] Coskun T, et al. Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a randomised, double-blind, placebo- and active-controlled phase 2 trial. Lancet Diabetes Endocrinol. 2025. https://doi.org/10.1016/S2213-8587(25)00092-0
[13] The Effect of Retatrutide on Kidney Parameters in Participants With Type 2 Diabetes or Overweight/Obesity. Kidney Int Rep. 2025. https://pubmed.ncbi.nlm.nih.gov/40630318/
[14] Pearson MJ, et al. Retatrutide And Lipid And Metabolite Profiles In Participants With Obesity With Or Without Type 2 Diabetes. J Clin Endocrinol Metab. 2026. https://doi.org/10.1210/clinem/dgag201
[15] Wen Y, et al. Decreases in circulating ANGPTL3/8 concentrations following retatrutide treatment parallel reductions in serum lipids. Diabetes Obes Metab. 2025. https://doi.org/10.1111/dom.16661

---

A measured reading of the retatrutide trial record — the Phase 2 endpoints set down and cited, the Phase 3 program noted as open, and nothing here prescribed, dispensed, or sold.